Seeking Alpha

Affymax (AFFY +4%) makes new 52-week highs after Stifel upgrades shares to Buy. The firm expects...

Affymax (AFFY +4%) makes new 52-week highs after Stifel upgrades shares to Buy. The firm expects Affymax's Peginesatide dialysis drug, which is set for a Q2 launch, to be "a disruptive force" in its target market, one that will put an end to the "monopoly pricing power" wielded by Amgen's (AMGN) Epogen.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector